-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
2021 will be the year when the fifth batch of centralized drug procurement will be implemented.
The 61 drugs will drop by an average of 55%, and the highest decline may even reach 98%.
Both the number of varieties and the purchase amount have reached a new high, which will benefit the majority of patients
.
Entering 2022, another wave of drug prices will be cut
.
From January 1, 2022, the new version of the National Medical Insurance Drug List will be officially implemented.
In this adjustment, a total of 74 drugs have been added to the list, and 11 drugs have been transferred out of the list
.
Judging from the negotiation situation, the average price of 67 drugs was reduced by 61.
71%
.
Among them, the rare disease drug Nosinagen Sodium, which costs 700,000 yuan per injection, has been significantly reduced in price, and will be included in the new national medical insurance drug list on January 1, 2022, and each injection will be about 30,000 yuan
.
In addition, from May 2022, the results of the sixth batch of national centralized drug procurement (insulin special) will be implemented.
A total of 42 varieties were selected in this centralized procurement, with an average price reduction of 48%, and the highest price reduction reached 74%
.
The 42 varieties include both domestic varieties and original research varieties.
Among them, domestic pharmaceutical companies Gan & Lee Pharmaceuticals and United Laboratories each won the bid for 6 products, Tonghua Dongbao 5, Hefei Tianmai 3, Sunshine Pharmaceutical 2, Wanbang Biochemical 2 1, Hisun Pharmaceutical 1
.
Among multinational pharmaceutical companies, Novo Nordisk won the bid for 7 products, Eli Lilly 5, Poland Baitong 3, and Sanofi 2
.
It is reported that Gan & Lee Pharmaceutical has an average drop of 65.
33%, and Tonghua Dongbao has an average drop of 41.
2%
.
Since January of this year, new news about centralized procurement has also been reported
.
According to news on January 10 at the national level, China will normalize and institutionalize the centralized procurement of drugs and high-value medical consumables.
By the end of 2022, the national and provincial centralized procurement of drugs will reach more than 350 in each province
.
On January 21, 2022, the seventh batch of the national procurement volume catalogue was released.
This batch of centralized procurement involves 58 varieties and 208 specifications, including omeprazole injection, meropenem, metoprolol and other products in the order of 100 million yuan.
Large varieties are listed
.
The notice shows that the reporting volume will be officially launched on January 26, and the provinces will import the historical procurement volume data in 2021 for reference by medical institutions.
Medical institutions must fill in the relevant drug procurement requirements as required, and submit the data before 24:00 on February 16
.
Before 17:00 on February 25, all provinces need to complete the review of relevant drug procurement requirements
.
It can be seen that the seventh batch of centralized procurement is already on the horizon
.
Up to now, six batches of national centralized drug procurement have been carried out, and the selected drugs have an average price reduction of 53%, covering hypertension, diabetes, hyperlipidemia, tumors, chronic hepatitis B and other drug fields
.
Data show that by the end of 2021, a total of 260 billion yuan in medical insurance and patient expenditures will be saved
.
Previously, for the next step in the centralized procurement of medicines and high-value medical consumables, the national level has pointed out the direction, including: focusing on chronic diseases and common diseases, continue to promote the centralized procurement of drugs at the national level, and carry out drugs outside the national centralized procurement.
Provincial or inter-provincial alliance procurement; gradually expand the coverage of centralized procurement of high-value medical consumables, and conduct centralized procurement at the national and provincial levels for orthopedic consumables, drug balloons, and dental implants that are of concern to the public; ensure long-term stability of selected drugs and consumables Supply, strengthen supervision, and ensure that the price of the selected products is not reduced in quality
.
At the same time, the National Medical Insurance Bureau has made it clear that during the "14th Five-Year Plan" period, the centralized procurement of drugs and medical consumables will be increased, and centralized procurement will be promoted to become the dominant model.
The scope of centralized procurement of high-value medical consumables
.
Overall, with the advancement of centralized collection, it will be a great boon for the majority of patients
.
The 61 drugs will drop by an average of 55%, and the highest decline may even reach 98%.
Both the number of varieties and the purchase amount have reached a new high, which will benefit the majority of patients
.
Entering 2022, another wave of drug prices will be cut
.
From January 1, 2022, the new version of the National Medical Insurance Drug List will be officially implemented.
In this adjustment, a total of 74 drugs have been added to the list, and 11 drugs have been transferred out of the list
.
Judging from the negotiation situation, the average price of 67 drugs was reduced by 61.
71%
.
Among them, the rare disease drug Nosinagen Sodium, which costs 700,000 yuan per injection, has been significantly reduced in price, and will be included in the new national medical insurance drug list on January 1, 2022, and each injection will be about 30,000 yuan
.
In addition, from May 2022, the results of the sixth batch of national centralized drug procurement (insulin special) will be implemented.
A total of 42 varieties were selected in this centralized procurement, with an average price reduction of 48%, and the highest price reduction reached 74%
.
The 42 varieties include both domestic varieties and original research varieties.
Among them, domestic pharmaceutical companies Gan & Lee Pharmaceuticals and United Laboratories each won the bid for 6 products, Tonghua Dongbao 5, Hefei Tianmai 3, Sunshine Pharmaceutical 2, Wanbang Biochemical 2 1, Hisun Pharmaceutical 1
.
Among multinational pharmaceutical companies, Novo Nordisk won the bid for 7 products, Eli Lilly 5, Poland Baitong 3, and Sanofi 2
.
It is reported that Gan & Lee Pharmaceutical has an average drop of 65.
33%, and Tonghua Dongbao has an average drop of 41.
2%
.
Since January of this year, new news about centralized procurement has also been reported
.
According to news on January 10 at the national level, China will normalize and institutionalize the centralized procurement of drugs and high-value medical consumables.
By the end of 2022, the national and provincial centralized procurement of drugs will reach more than 350 in each province
.
On January 21, 2022, the seventh batch of the national procurement volume catalogue was released.
This batch of centralized procurement involves 58 varieties and 208 specifications, including omeprazole injection, meropenem, metoprolol and other products in the order of 100 million yuan.
Large varieties are listed
.
The notice shows that the reporting volume will be officially launched on January 26, and the provinces will import the historical procurement volume data in 2021 for reference by medical institutions.
Medical institutions must fill in the relevant drug procurement requirements as required, and submit the data before 24:00 on February 16
.
Before 17:00 on February 25, all provinces need to complete the review of relevant drug procurement requirements
.
It can be seen that the seventh batch of centralized procurement is already on the horizon
.
Up to now, six batches of national centralized drug procurement have been carried out, and the selected drugs have an average price reduction of 53%, covering hypertension, diabetes, hyperlipidemia, tumors, chronic hepatitis B and other drug fields
.
Data show that by the end of 2021, a total of 260 billion yuan in medical insurance and patient expenditures will be saved
.
Previously, for the next step in the centralized procurement of medicines and high-value medical consumables, the national level has pointed out the direction, including: focusing on chronic diseases and common diseases, continue to promote the centralized procurement of drugs at the national level, and carry out drugs outside the national centralized procurement.
Provincial or inter-provincial alliance procurement; gradually expand the coverage of centralized procurement of high-value medical consumables, and conduct centralized procurement at the national and provincial levels for orthopedic consumables, drug balloons, and dental implants that are of concern to the public; ensure long-term stability of selected drugs and consumables Supply, strengthen supervision, and ensure that the price of the selected products is not reduced in quality
.
At the same time, the National Medical Insurance Bureau has made it clear that during the "14th Five-Year Plan" period, the centralized procurement of drugs and medical consumables will be increased, and centralized procurement will be promoted to become the dominant model.
The scope of centralized procurement of high-value medical consumables
.
Overall, with the advancement of centralized collection, it will be a great boon for the majority of patients
.
